The role of iron status biomarkers in von Hippel-Lindau disease.

The role of iron status biomarkers in von Hippel-Lindau disease. - Iron and VHL (iVHL)

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON57792

Enrollment

Registered

2025-06-25

Start date

2026-04-23

Completion date

Unknown

Last updated

2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

von-Hippel Lindau Syndrome

Interventions

None listed

Eligibility

Age

18 Years to 64 Years

Inclusion criteria

Inclusion criteria: In order to be eligible to participate in this study, a subject must meet all of the following criteria: - Genetically or clinically diagnosed VHL syndrome in accordance with International Guidelines - The subject is at least 18 years of age - Subjects have to be able to read and understand the Dutch language

Exclusion criteria

Exclusion criteria: A potential subject who meets any of the following criteria will be excluded from participation in this study: - pregnancy - Current use of drugs interfering with iron biomarkers, like belzutifan, EPO or HIF-stabilizers - The subject is 75 years or older

Design outcomes

Primary

Measure	Time frame
iron status (serum ferritin, transferrin, serum iron) and related biomarkers (hepcidin, EPO, and soluble transferrin receptor)	—

Countries

Netherlands

Outcome results